+$29.5M
Net Activity
Institutions Holding
82
Popularity Rank
#4892
Avg Weight
0.94%
Total Value
$373.7M
82 institutions currently hold XFOR, with 38 net buyers and 33 net sellers this quarter.
Institutional Moves (Q1 2026)
Neutral
Based on recent trading activity
Net Selling Institutions
33
Net Buying Institutions
38
Top 5 by Value
+$170.5M
Total Buy Value
$119.8M
Total Sell Value
38
Net Buyers
33
Net Sellers
No Form 144 planned sale filings in the last 90 days
No Schedule 13D/13G filings for this ticker
1
Filings (14d)
On June 30, 2026, X4 Pharmaceuticals appointed Kelly Gold as a Class II director, effective July 1, expanding the board from five to six members. Gold brings deep financial expertise as the CFO of CAMP4 Therapeutics, with prior senior roles at Biogen and Deutsche Bank. She will also serve on the Audit Committee.
View Full Filing (SEC EDGAR)The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter